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Abstract: 
DNA vaccination is effective in inducing potent immunity in mice; however it appears to be 
less so in large animals. Increasing the dose of DNA plasmid to activate innate immunity has 
been shown to improve DNA vaccine adaptive immunity. Retinoic acid-inducible gene I 
(RIG-I) is a critical cytoplasmic double-stranded RNA pattern receptor required for innate 
immune activation in response to viral infection. RIG-I recognise viral RNA and trigger 
antiviral response, resulting in type I interferon (IFN) and inflammatory cytokine production. 
In an attempt to enhance the antibody response induced by BVDV DNA in cattle, we 
expressed BVDV truncated E2 (E2t) and NS3 codon optimised antigens from antibiotic free-
plasmid vectors expressing a RIG-I agonist and designated either NTC E2t(co) and NTC 
NS3(co). To evaluate vaccine efficacy, groups of five BVDV-free calves were 
intramuscularly injected three times with NTC E2t(co) and NTC NS3(co) vaccine plasmids 
individually or in combination. Animals vaccinated with our (previously published) 
conventional DNA vaccines pSecTag/E2 and pTriExNS3 and plasmids expressing RIG-I 
agonist only presented both the positive and mock-vaccine groups. Our results showed that 
vaccines coexpressing E2t with a RIG-I agonist induced significantly higher E2 antigen 
specific antibody response (p < 0.05). Additionally, E2t augmented the immune response to 
NS3 when the two vaccines were delivered in combination. Despite the lack of complete 
protection, on challenge day 4/5 calves vaccinated with NTC E2t(co) alone or NTC E2t(co) 
plus NTC NS3(co) had neutralising antibody titres exceeding 1/240 compared to 1/5 in the 
mock vaccine control group. Based on our results we conclude that co-expression of a RIG-I 
agonist with viral antigen could enhance DNA vaccine potency in cattle. 
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Introduction: 
BVDV is endemic throughout much of the world. Even a clinically mild infection can 
significantly impact animal productivity [1]. Infection of the foetus during the first trimester 
may result in abortion or calves that are born persistently infected (PI) and continuously shed 
high levels of virus [1]. Strategies to control BVDV infection include culling of PI animals, 
enhanced biosecurity and the use of vaccines. Currently modified live and inactivated 
vaccines are used to protect cattle from BVDV. A major shortcoming of existing vaccines is 
the lack of a marker status to differentiate between vaccinated and naturally-infected animals. 
The positive ssRNA BVDV genome encodes structural (core, Erns, E1 & E2) and non-
structural proteins (Npro, NS2, NS3, NS4a/b, NS5a/b) [2], [3]. The major envelope 
glycoprotein (E2) and the non-structural protein 3 (NS3) have been studied as candidates for 
subunit vaccine [4], [5], [6], [7]. Cattle vaccinated with inactivated BVDV elicit high levels 
of neutralising anti-E2 antibody and are protected from viraemia and nasopharyngeal 
shedding [8]. NS3 is conserved across strains [3], [9] and it may assist in induction of cross-
strain immunity. Our previous study demonstrated partial protection in cattle vaccinated with 
NS3 DNA vaccine [7]. These facts supported the design of BVDV marker subunit vaccine 
based on both E2 and NS3. 
DNA vaccination emerged as an efficient means of eliciting cell mediated and humoral 
responses in small animal models against a number of antigens from parasites, bacteria and 
viruses. Despite the approval of four DNA vaccines in fish, horses, dogs and pigs in 
veterinary medicine [10], [11], [12], [13], DNA vaccine potency in large animals has not 
been encouraging. It remains an immunological problem that has to be overcome to enhance 
DNA vaccine potency. 
Innate immune cells recognise specific pathogen associated molecular patterns via their 
pattern recognition receptors and thereby activate the adaptive immunity [14]. Thus, 
increasing innate immunity through inclusion of novel backbone-encoded innate immunity 
agonists can improve DNA vaccine induced immune responses. RIG-I is a cytoplasmic 
dsRNA pattern receptor required for innate immune activation in response to viral infection. 
Following RNA virus infection, RIG-I become activated through binding to its ligand 
(uncapped 5′-PPP-containing short, blunt dsRNA); this leads to type I IFN and inflammatory 
cytokines production. RNA polymerase III (Pol III) promoters are small, expressed at high 
levels and have the potential to retain 5′-PPP (J. A. Williams, world patent application 
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WO2006078979). Integration of RNA pol III promoter expressed RIG-I ligand into DNA 
vaccine backbone acts as a RIG-I-agonist resulting in enhanced plasmid immunostimulation 
and improved adaptive immune responses in mice [15], [16], [17]. 
To examine the effect of incorporation of RIG-I agonist on DNA vaccine potency in large 
animals, we compared the potency of DNA marker vaccine expressing E2t or NS3 in 
presence of RIG-I agonist in terms of viral protein-specific and neutralising antibody 
responses and protection efficacy in cattle. 
2. Materials and methods 
2.1. Cells and viruses 
BVDV-free MDBK cells were cultured in Minimum Essential Medium (MEM) containing 
10% BVDV-free foetal bovine serum (FBS) (Sigma-Aldrich, UK), 1% glutamine and 1% 
antibiotic/antimycotic (Life Technologies, UK). The non-cytopathic BVDV type-1a strain 
Ky1203, the cytopathic NADL-1a strain [2] and non-cytopathic 456497-1a were propagated 
in MDBK cells. COS-7 cells were maintained in Dulbecco's Minimum Essential Medium 
(DMEM) (Sigma-Aldrich, UK) supplemented with 10% FBS, 2 mM l-glutamine, and 1% 
antibiotic/antimycotic. 
2.2. Plasmids cloning 
The antibiotic-free selection NTC838 series expression vectors utilised herein contain a 150 
bp RNA-based selectable marker (RNA-OUT) that confers sucrose resistance onto 
Escherichia coli strain NTC4862 (DH5α-derived with chromosomally integrated RNA-IN-
SacB) by suppression of SacB (levansucrase) translation. This enabled antibiotic-free plasmid 
selection in sucrose containing media [18]. The codon-optimised (co) E2t and NS3 genes 
were designed using highly expressed bovine gene codon usage and synthesised by GeneArt. 
The synthetic genes were cloned into the eRNA41H RIG-I agonist-encoding NTC8382-
eRNA41H VA2 vector [15] to make the NTC E2t(co) and NTC NS3(co) vectors (Fig. 1). A 
tissue plasminogen activator (tPA) signal sequence was included in the E2t vector, to provide 
a signal sequence for secretory E2t expression. The NS3 gene was expressed without a 
secretory signal since it is an internal protein. The parent NTC8382-eRNA41H VA2 vector 
without transgene was used as a mock vaccine. The NTC8382-eRNA41H VA2 derived 
vectors were produced in NTC4862 using antibiotic-free, sucrose media selection. All inserts 
and vaccine clones were confirmed by sequencing. For DNA vaccination, 10–20 mg of 
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endotoxin-free plasmid DNA of each clone was produced and formulated in sterile water. 
Plasmids expressing native viral E2 truncated (pSecTag/E2) and NS3 (pTriExNS3) are 
described previously [4], [5], [6], [7]. 
2.3. Transfection and immunostaining 
COS-7 cell were seeded in a 24-well plate (5 × 105 cells/ml), and grown to 70–80% 
confluence prior to transfection. Plasmid DNA expressing NTC E2t(co), NTC NS3(co), 
pSecTag/E2 or pTriExNS3 were transfected using lipofectamine LTX (Life Technologies) as 
described before [19]. Cells were immunostained for BVDV as detailed previously [19]. 
2.4. Experimental design 
2.4.1. DNA vaccination 
All animal procedures were approved by the local ethical review process and met all those 
requirements of the Home Office (Scientific procedures) Act 1986 under their code of 
practice. Twenty five mixed breed calves (5–8 months old) were sourced and confirmed 
BVDV antibody- and antigen-free prior to the study. Calves were housed in a purpose built 
barn with biosecurity measures in place to avoid possible exposure to adventitious pathogens. 
Calves were allocated to five treatment groups according to random block design based on 
age. All vaccines were administered intramuscularly at a dose of 500 μg in 4 ml PBS. 
Treatment groups were as in Table 1. Animals received 3 vaccinations (V1,V2,V3) at 21 days 
intervals. 
Treatment group Vaccine formula Vaccine type 
Group 1 NTC NS3(co) Candidate vaccine 
Group 2 NTC NS3(co) + NTC E2t(co)* Candidate vaccine 
Group 3 NTC E2t(co) Candidate vaccine 
Group 4 pTriExNS3 + pSecTag/E2* Positive control 
Group 5 Parent NTC8382-eRNA41H VA2 
Mock vaccine (vector 
without transgene) 
* “+” Indicates co-administration of two vaccine formulas. 
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2.4.2. Virus challenge and sampling 
Pre-challenge (baseline) measurements of rectal temperatures and haematological profiles 
commenced on study day -2, 1 and on challenge day (day 0). On day 0, all animal were 
challenged with 10 ml dose containing 2.39 x106 TCID50 of early passage of field isolate 
456497 (BVDV type 1a strain) which was subsequently back titrated after challenge (1 x 
106/ml). Challenge inoculum was instilled into the nares upon inspiration. Thereafter, 
measurements of all parameters were made daily until study day 14 (except day 1 and 2), 
with a final time point on day 21. Rectal temperatures were taken daily, until day 10, and 
EDTA blood samples for haematology until day 14. EDTA blood samples were processed 
using an automated haematological analyser (Cell Dyn, Abbot) to determine total and 
differential leucocyte counts. Lymphocytes, neutrophils and monocytes were all quantified in 
the differential count. Nasal swabs and additional blood samples were taken on each occasion 
for virus isolation and for serology on day 0, 3, 5, 6, 7, 10, 14 and 21. All calves were 
weighed and euthanised on study day 28 post challenge. 
2.5. Virus isolation from buffy coat samples and nasopharyngeal swabs 
All EDTA blood samples taken for virology from day 0 onwards were prepared by extracting 
and washing the total white blood cell pellet. The presence of virus was then determined in 
these samples after dilution in 1 ml maintenance medium. Briefly samples were inoculated in 
duplicate onto freshly prepared FBL cells in 24-well plates and incubated for 5 days. After 
freeze thaw and dilution of material the inoculum was passed once more onto cells seeded on 
sterile glass coverslips and incubated for a further 5 days. Presence of virus was detected via 
immunofluorescence staining using a hyperimmune polyclonal bovine anti-BVDV serum and 
a Cy-3-conjugated anti-bovine antibody (Stratech, UK). Scoring was performed using a 
fluorescence microscope and appropriate filter sets. To detect BVD virus in nasopharyngeal 
swabs, the samples were diluted (1:5) in maintenance medium (Medium Essential Medium 
containing 2% foetal calf serum and antibiotic/antimycotic solution) and then inoculated, in 
duplicate, onto freshly prepared FBL cells in 24-well plates and incubated for 5 days at 37 ºC. 
After one round of freeze-thaw and dilution of material, the inoculum was passed once more 
onto fresh FBLs and incubated for a further 5 days. Presence of virus was detected via 
immunofluorescence staining as described previously [20]. 
2.6. Serology 
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Levels of neutralising antibody to homologous (Ky1203nc) and heterologous (NADL) were 
established as described before [20]. The results are expressed as the reciprocal of the serum 
dilution at which 50% of the virus was neutralised. Detection of antibody response to whole 
BVDV virus, in serum was performed using indirect ELISA (23) with some modification. 
The E2 specific antibody ELISA, using purified E2 protein, was performed as described 
previously [19]. Levels of antibody to E2 protein were determined as ELISA optical density 
values (OD) where cut off was considered 0.5 (mean OD of mock vaccine sera at day 0 + 
3SD). Anti-NS3 specific antibody response was performed using the PrioCHECK 
commercial Kit following the manufacturer protocol where results are expressed as 
percentage of inhibition, inhibition values of > 50 were considered positive.    
 
2.7. Statistical analysis 
Antibody responses were compared between groups using analysis of variance (ANOVA) 
techniques and between two groups using t test. All tests were carried out using GraphPad™ 
Software. Statistical significance was claimed at p < 0.05. 
 
3. Results. 
3.1. Plasmid cloning and in vitro expression of viral antigen proteins 
Bovine codon optimized E2t (co) and NS3(co) synthetic genes were cloned into a RIG-I 
agonist encoding, antibiotic free selection vector NTC8382-eRNA41H-VA2 [15] (Figure 1). 
Successful cloning of E2t(co) and NS3(co) was evident by in vitro expression in COS-7 cells. 
Diffuse fluorescence was observed in the cytoplasm in cells transfected with plasmids 
expressing E2t or NS3 when immunostained with the BVDV hyperimmune serum (Fig. 2). 
These results confirm that E2t and NS3 proteins were expressed. 
3.2. Clinical and haematological observations 
3.2.1. Rectal temperature 
The pattern of pyrexia observed was characteristic of BVDV infection. The mean rectal 
temperatures (°C) of each vaccine group are presented in Fig. 3A. The pre-challenge (day −2 
to 0) temperatures were similar for all groups. The mean group temperature values remained 
within the normal range (38.5–39.5 °C) throughout the study except for a transient rise 
recorded in all groups on day 8 with the highest mean temperature noted in vaccine group 
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(NTC E2t(co)). No significant difference was observed between vaccine groups and the mock 
group. 
3.2.2. Haematology 
A typical leucopenia was observed from day 3 post-challenge in all groups with no 
significant difference between vaccine groups and the mock group (Fig. 3B). The latter had 
51.1% reduction against baseline leucocyte counts compared to a 38.1% reduction in NTC 
NS3(co) vaccine group, 38.3% and 36.6% in NTC NS3(co) + NTC E2t(co) and NTC E2t(co) 
vaccine groups, respectively. The positive control group however had 46.5% reduction in 
leucocytes counts. Following from day 3 post-challenge, leucocytes counts started increasing 
although a reduction was seen also on day 7 in NTC E2t(co) group. However by day 10, 
blood counts returned to approximately near pre-challenge values in all groups. 
3.3. Antibody response  
Specific antibody response to BVDV E2 and NS3 antigens following vaccination and 
challenge were determined by ELISA (Fig. 4). 
3.3.1. Anti-NS3 antibody response 
On day of challenge, sero-conversion to NS3 was evident in 3 calves in NTC NS3(co) + NTC 
E2t(co) group, but not in NTC NS3(co) group (Fig. 4A). However, by day 14 post-challenge 
anti-NS3 antibodies were detected in all calves in NTC NS3(co) group, 4 calves in NTC 
NS3(co) + NTC E2t(co), in one calf in NTC E2t(co) and pTriExNS3 + pSecTag/E2 
compared to 2 calves in the mock group. NS3-seroconversion continued to rise to 100% by 
day 28 in all animals vaccinated with NTC NS3(co) or mock vaccine and to 80% in 
pTriExNS3 + pSecTag/E2 group. 
3.3.2. Anti-E2 antibody response 
On challenge day, 3 calves in each of vaccine groups NTC NS3(co) + NTC E2t(co) and NTC 
E2t(co) had significantly detectable level of anti-E2 antibody compared to other groups (p 
value < 0.05). By 7 days post-challenge, anti-E2 sero-conversion in these 2 groups increased 
to 4/5 and 5/5 calves, respectively. This level continued to rise in all 10 animals and sustained 
until end of the study (Fig. 4B). 
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Delay in antibodies to E2 was seen in pTriExNS3 + pSecTag/E2 group, where sero-
conversion was detected 7 days post-challenge in 3/5 calves and in all calves by 14 days. 
Anti-E2 antibody response was detected at low prevalence in NTC NS3(co) and mock groups 
by day 14 post-challenge and increased to 4 and 5 calves, respectively, albeit at a lower level, 
by 28 days. 
3.3.3. Neutralising antibody 
 
3.3.3.1. Homologous neutralising response 
 
By challenge day, all calves vaccinated with NTC NS3(co) + NTC E2t(co) or NTC E2t(co) 
had generated neutralising titres (mean: >493) to the homologous virus compared to 4/5 
calves in pTriExNS3 + pSecTag/E2 (mean: >285) (Tables 2 - 3). The levels of neutralising 
titres in these groups continued to rise throughout reaching high titres (≥10,240) in all 
animals. In NTC NS3(co) and mock groups however, neutralising antibodies were detected 
only at day 14 at lower titres (80–1280 and 80–905, respectively) and continued to rise to the 
end of the study reaching the highest titre of 5120 and 1810 in some of these animals, 
respectively. 
 
3.3.3.2. Heterologous neutralising response 
 
Heterologous neutralising antibody titres to NADL strain were also detected on challenge day 
in all E2-vaccinated calves except one calf in pTriEx/NS3 + pSecTag/E2 group (Tables 2-3). 
The titres were higher in the group vaccinated with NTC E2t(co) with 3 calves showing 
≥640. These titres continued to rise throughout to >640 in all calves by day 14 post challenge. 
In NTC NS3(co) and mock groups however, heterologous neutralising titres were detected 
only 14 days post-challenge (40–≥640 and 20–≥640, respectively). 
 
3.4. Virus isolation 
Virus isolation from nasal swab and buffy coat samples was undertaken. All calves were 
negative for virus on the day 0. Virus was recovered from nasal swab samples between days 
5–7. In the mock group, infectious virus was first isolated on day 5 from one calf and on day 
7 from 4 calves. In the vaccinated groups however, infectious virus was isolated from the 
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nasal swabs on days 5–7 from only 1 or 2 calves including pTriExNS3 + pSecTag/E2 group, 
although in one calf vaccinated with NTC NS3(co) the virus was detected on day 3. The 
results from buffy coat samples showed that infectious virus was isolated only in one calf 
from the mock group on day 6. This animal remained viraemic on days 7 and 10. No virus 
was isolated from buffy coat samples from vaccine groups except from one calf (day 5) 
vaccinated with NTC E2t(co). 
 
4. Discussion 
Increasing levels of plasmid vector-mediated activation of innate immune signalling 
pathways is an approach to improve DNA vaccine-adaptive immunity. In this study we aimed 
to incorporate the RIG-1 agonist eRNA41H into plasmid vector expressing E2 or NS3 BVDV 
antigens as part of an ongoing effort to develop an effective marker DNA vaccine for BVDV. 
The incorporation of RIG-1 agonist was used to enhance the humoral immune response of an 
influenza HA DNA vaccine [15]. In other study, RIG-I agonist have been used as adjuvant in 
combination with influenza virus inactivated vaccine resulting in enhanced anti-influenza 
HA-specific IgG. This adjuvant was equally effective at increasing the efficiency of an 
influenza inactivated vaccine as a poly(I·C)- or a squalene-based adjuvant [21]. The adjuvant 
effect of RIG-I agonist was further demonstrated in a recent study in mice when co-
administering with inactivated influenza vaccine led to a robust HA antibody response and 
protection against virus challenge [22]. In the present study, we generated DNA vaccines 
based on E2 and NS3 with a DNA backbone containing RIG-I agonist and designed in 
compliance with Food and Drug Administration (FDA) regulatory guidance's [16], [18], [23]. 
Additionally, taking into account the merit of codon optimisation to host sequence, all 
vaccines encoding proteins were codon optimised to Bos taurus where their immunogenicity 
and protective efficacy were assessed in calves. 
The selection of E2 and NS3 proteins as antigen targets for a BVDV vaccine has been 
established previously. Our own studies and that of others tested the efficacy of E2-based 
vaccines and showed an encouraging level of partial protection from BVDV challenge [6], 
[20], [24], [25], [26], [27], [28], [29]. Vaccination of cattle with the DNA vaccine expressing 
the highly immunogenic E2 induces protective immunity [6]. We have previously shown that 
immunity to BVDV in cattle can be augmented by vaccination with the highly immunogenic 
NS3 protein [7]. 
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Transient leucopenia and biphasic febrile response, with few overt signs of infection are 
typical feature observed in susceptible healthy cattle following challenge with BVDV-1 virus. 
The virus replicates in the nasal epithelium before spreading to the tonsils [30]. Thereafter, 
virus dissemination occurs through the blood and lymphatic system, with virus being isolated 
from the blood around 3 days post-challenge. A viraemic period of 7–10 days is normally 
observed. 
In this study, a rise in rectal temperature above the normal range was recorded in all groups 
on day 8 post-challenge and returned to normal range by day 9. There was no difference in 
transient pyrexia between vaccinated animals and the mock group. 
Transient leucopenia was observed by three days post-challenge in all vaccinated groups and 
mock group. In NTC E2t(co) vaccine group, leucopenia was evident on day 7 but returned to 
pre-challenge level by day 10 (Fig. 3B). In NTC NS3(co) + NTC E2t(co) and the positive 
control group, white blood counts returned to near pre-challenge values by day 10. In 
contrast, although not significant, leucopenia was more pronounced in mock vaccine group 
on day 3 post-challenge with no difference to vaccine groups on day 6–7, returning to near 
pre-challenge values by day 10. 
Prevention of viraemia is a key parameter for a BVDV vaccine, since viraemia in a pregnant 
animal may result in vertical transmission of infectious virus to the foetus [31], [32]. In this 
study reduction in virus isolation observed in nasal swab samples from NTC NS3(co) + NTC 
E2t(co) group is promising where BVDV was isolated from 2/5 calves for one day only. 
These results were equivalent to that of the positive control group (ptriExNS3 + pSecTag/E2) 
and comparable to partial protection achieved in our previous studies [6], [7]. Similarly, in 
calves vaccinated with NTC E2t(co) alone, the virus was detected in 2 calves but for one and 
two days. In NTC NS3(co), however the virus was isolated from all calves for one or two 
days highlighting the importance of the role of the immune response to E2 in the control of 
BVDV infection. The virus was isolated from 4/5 calves in the mock group. 
The results of virus isolation from buffy coat showed the virus can only be isolated on day 5 
from one calf vaccinated with NTC E2t(co) whereas no virus was isolated in any of other 
animals in this group or from any of the other vaccine groups. However, the results of BVDV 
isolation from the mock group was rather disappointing where the virus was isolated from 
only one animal for three days (6, 7 and 10). 
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One of the key characteristic features of vaccine efficacy is the induction of sufficient 
humoral immune response to afford protection. As such, the levels of antibody response 
generated against BVDV proteins and virus neutralising antibody response were assessed. 
High levels of anti-NS3 antibodies were observed in all NS3-containing vaccines. Anti-NS3 
antibody response was evident on challenge day when NTC NS3(co) vaccine was co 
administered with NTC E2t(co) and not in NTC NS3(co) group suggesting that E2 augment 
immune response to NS3. Overall vaccination with NTC NS3(co) in combination with or 
without E2t(co) induced higher anti-NS3 antibody response as compared to pTriExNS3 + 
pSecTag/E2 (Fig. 4A). These results highlight the effect of RIG-I agonist in enhancing the 
immune response to NS3. The effect of RIG-I agonist was also clear at the level of immune 
response to E2 protein. Animals vaccinated with NTC E2t(co) alone or co-administered with 
NTC NS3(co) induced anti-E2 antibody response on the challenge day whilst no response 
was seen in any of the positive or mock groups. The anti-E2 antibody level increased post-
challenge including the positive control group but the response remained lower in the latter 
group. Overall, NTC NS3(co) and NTC E2t(co) vaccines primed the immune response to the 
challenge virus. We showed that immune response to NS3 was augmented when NTC 
NS3(co) was administered with NTC E2t(co) suggesting RIG-I agonist enhanced to the 
antibody response to BVDV. 
Studies have shown that passive antibody provides protection against systemic BVDV 
infection [33], [34]. Virus neutralising antibodies have proven to be partially protective at a 
titre of 1/160 and fully protective at a titres of 1/240 [33]. The levels of neutralising antibody 
titres raised against homologous and heterologous strains were assessed. On challenge day, 
both vaccine groups (NTC E2t(co) and NTC NS3(co) + NTC E2t(co)) had neutralising titre 
>240 in 4/5 animals with the remaining animal >160. In contrast, only one calf had 
neutralising titre >240 in pTriEx NS3 + PSecTag/E2 vaccinated group. These results 
coincided with the high E2-antibody response in these two vaccine groups suggesting the 
importance of RIG-I agonist. The neutralising response continued to rise in both vaccine 
groups containing NTC E2t(co) and pTriExNS3 + pSecTag/E2 reaching >7.6 and >6.3 fold 
increase, respectively, to that induced in the mock vaccine 3 weeks post-challenge. In the 
NTC NS3(co) vaccine group, neutralising titre was 1.5 fold higher than in the mock group. 
Heterologous neutralising antibody response was also evident in this study. On challenge day, 
3/5 and 2/5 animals in NTC E2t(co) and NTC NS3(co) + NTC E2t(co) groups, respectively, 
had >240 titres compared to one calf at 160 titre in pTriEx NS3 + pSecTag/E2 group. The 
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heterologous response was primed 7 days post-challenge but remained higher in NTC 
E2t(co)-containing vaccines (mean titre: >427 and >493) than in pTriExNS3 + pSecTag/E2 
group (mean titre: >288). 
In conclusion, this study endorsed the importance of RIG-I agonist incorporation in DNA 
vaccine backbone to enhance vaccine potency in large animals including cattle. Investigation 
of the cytokine profiles induced by the DNA vaccine incorporating BVDV antigen and RIG-I 
agonist, vaccine dose and delivery routes warrant further study to achieve complete 
protection. 
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Figure 1. Antibiotic-free vectors co-expressing a RIG-I agonist (immunostimulatory 
RNA) with BVDV NS3 antigen (A) and BVDV E2t antigen (B) 
(A) 
(B)  
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Figure 2. In vitro expression of E2 and NS3 viral antigens in COS-7 cells by 
different DNA vaccine vectors. Transfected cells were treated with BVDV 
hyperimmune polyclonal serum and indirect immunofluorescence staining. 
Diffuse cytoplasmic staining was observed in cells transfected with vaccines 
expressing codon and non-codon optimised E2t or NS3. Granular fluorescence 
staining was also observed in cells transfected with vaccine expressing E2t, 
suggesting an association of the expressed protein with the cell membranes. 
 
  
 NTC E2t (co)                   NTC NS3 (co)  
  pSecTag/E2                       pTriExNS3    
E2 t- mock                         NS3 - mock 
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Figure 3. Clinical manifestation (rectal temperature and leucopenia fluctuation) 
following BVDV challenge (day 0) of calves vaccinated with NTC NS3(co), NTC 
NS3(co) + NTC E2t(co), NTC E2t(co), pTriExNS3 + pSecTag/E2 or mock 
vaccine. (A) Mean rectal temperature + SD (B) Mean total leucocyte counts 
expressed as a percentage of pre-challenge values. 
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Figure 4.  Serum antibody responses after challenge (day 0) in calves 
vaccinated three times; with NTC NS3(co), NTC NS3(co) +NTC E2t(co), NTC 
E2t(co), pTriExNS3 + pSecTag/E2 or mock vaccinated. Data shows (A) anti-
BVDV NS3-antibody response presented as Percentage of Inhibition (PI), 
where PI > 50 considered positive, (B) anti-E2 antibody response, where 
results are recorded as mean OD values at 1/500 (at log10 2.69897)  dilution. 
Bars represent + SD.     
 
(A)
(B)
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Table 2. Homologous neutralisation titres 
Vaccine 
Calf 
ID 
Days post  challenge 
Day V3 Day 0 Day 7 Day  14 Day 21 
NTC NS3(co) 
558  <10  <10   <40   226    1280 
575  <10  <10   <40   905    1810 
576  <10  <10   <40   160    1280 
590  <10  <10   <40     80      640 
606    20  <10    <40  1280     5120 
NTC NS3(co) + 
NTC E2t(co) 
564 >640 >640 >2560 >2560 >10240 
567  <10  320   1280 >2560 >10240 
579  <10  226     320 >2560 >10239 
595  160 >640 >2560 >2560 >10239 
605  113 >640 >2560 >2560 >10240 
NTC E2t(co) 
560 <10 >640   1280 >2560 >10240 
570 <10  453     905 >2560 >10240 
583 320 >640 >2560    905 >10239 
593 <10  226   1280 >2560 >10240 
602 453 >640    2560 >2560 >10240 
pTriExNS3+ 
pSecTag/E2 
563 <10  226     226 >2560 >10239 
568 <10  160     640 >2560 >10240 
581 <10  113   1280 >2560 >10240 
588 <10  <10    <40    453     1810 
607 453 >640    905 >2560 >10240 
Mock 
565 <10  <10    <40    905      905 
566 <10  <10    <40     80    1810 
574 <10  <10   <40   113      453 
586 <10  <10   <40   160    1810 
596 <10  <10   <40   640    1810 
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Table 3. Heterologous neutralising titres 
Vaccine Calf ID Days post  challenge 
Day V3 Day 0 Day 7 Day  14 
NTC NS3(co) 
558 <10 < 10  <10   320 
575 <10 <10  <10     80 
576 <10 <10  <10 >640 
590 <10 <10  <10     40 
606 <10 <10  <10   640 
NTC NS3(co) +  
NTC E2t(co)  
564 226 453 >640 >640 
567   10   80  453 >640 
579 <10   20    80 >640 
595 <10 453  640 >640 
605   40 113  320 >640 
NTC E2t(co) 
560    57 >640 >640 >640 
570 <10  160   227 >640 
583  56 >640 >640 >640 
593   10  113   320 >640 
602 113 >640 >640 >640 
pTriExNS3 + 
pSecTag/E2 
563 <10    20   20 >640 
568 <10   40  453 >640 
581 <10   28 >640 >640 
588 <10 <10  <10 >640 
607   80 160  320 >640 
Mock 
565 <10 <10 <10   40 
566 <10 <10 <10  640 
574 <10 <10 <10   20 
586 <10 <10 <10  226 
596 <10 <10 <10 >640 
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Table 3. Virus isolation from buffy coat and nasal swabs following virus 
challenge (day 0) with 2.39 x106 TCID50 of the BVDV field isolate 456497. (+) 
indicates virus isolation, (-) indicate no virus was isolated. 
Vaccine 
Calf 
ID 
Buffy coat Nasal swabs 
Days post challenge Days post Challenge 
0 3 5 6 7 10 0 3 5 6 7 10 
NTC 
NS3(co) 
558 - - - - - - - + - - - - 
575 - - - - - - - - - + - - 
576 - - - - - - - - + - - - 
590 - - - - - - - - - + + - 
606 - - - - - - - - - - + - 
NTC 
NS3(co) + 
NTC 
E2t(co) 
564 - - - - - - - - - - + - 
567 - - - - - - - - - - - - 
579 - - - - - - - - - - - - 
595 - - - - - - - - - + - - 
605 - - - - - - - - - - - - 
NTC 
E2t(co) 
560 - - - - - - - - - - - - 
570 - - - - - - - - - + + - 
583 - - - - - - - - - + - - 
593 - - - - - - - - - - - - 
602 - - + - - - - - - - - - 
pTriExNS3 
+ 
pSecTag/E2 
563 - - - - - - - - - + - - 
568 - - - - - - - - - - - - 
581 - - - - - - - - - - - - 
588 - - - - - - - - + - - - 
607 - - - - - - - - - - - - 
Mock 
565 - - - - - - - - - - + - 
566 - - - - - - - - - - - - 
574 - - - - - - - - - - + - 
586 - - - - - - - - - - + - 
596 - - - + + + - - + - + - 
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